VS
Vivek K. Subbiah
Highly rated in
55
conditions

Dr. Vivek K. Subbiah

Physicians Referral Service
Houston, TX
Highly rated in
55
conditions
Specialties:Pediatrics | Pediatric Hematology Oncology | Hematology Oncology
Experience:21 Years
Clinical Trials:Currently Recruiting for 12 Trials
Accepts:New PatientsMedicare
Highly rated in
55
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Vivek K. Subbiah's experience treating your condition:
About Dr. Vivek K. Subbiah

Vivek Subbiah is a Pediatrics specialist and a Pediatric Hematologist Oncology expert in Houston, Texas. Subbiah has been practicing medicine for over 21 years and is highly rated in 55 conditions, according to our data. His top areas of expertise are Medullary Thyroid Carcinoma, Adult Soft Tissue Sarcoma, Thyroid Cancer, Gamma Knife Radiosurgery, and Bone Marrow Transplant. He is licensed to treat patients in Texas. Subbiah is currently accepting new patients.

His clinical research consists of co-authoring 419 peer reviewed articles and participating in 36 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Vivek K. Subbiah it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Vivek K. Subbiah accepts the following insurance:

  •  Ambetter
Locations
1515 Holcombe Blvd, Houston, TX 77030
Background & Education
Graduate Institution
Other, 2002
Specialties
Pediatrics
Pediatric Hematology Oncology
Hematology Oncology
Licenses
Pediatric Hematology-Oncology in TX
Hospital Affiliations
University Of Texas MD Anderson Cancer Center
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

36 Clinical Trials
A Phase 1 Trial of Vandetanib (a Multi-Kinase Inhibitor of EGFR, VEGFR, and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer
Enrollment Status: Recruiting
Publish Date: December 12, 2022
Intervention Type: Drug, Other
Study Phase: Phase 1
A Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL-15/sIL-15Rα)) in Combination With Spartalizumab in Patients With Check Point Inhibitor (CPI) Relapsed Advanced Solid Tumors and Lymphoma
Enrollment Status: Recruiting
Publish Date: December 01, 2022
Intervention Type: Drug
Study Drug: NIZ985 and Spartalizumab
Study Phase: Phase 1
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Enrollment Status: Recruiting
Publish Date: December 01, 2022
Intervention Type: Drug
Study Drugs: INBRX-109 Tetravalent DR5 Agonist AntibodyCarboplatinCisplatinPemetrexed5-FluorouracilIrinotecan
Study Phase: Phase 1
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression
Enrollment Status: Recruiting
Publish Date: November 21, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
TCF-001 TRACK (Target Rare Cancer Knowledge) Study
Enrollment Status: Recruiting
Publish Date: October 24, 2022
Intervention Type: Diagnostic Test
Study Phase: Not Applicable
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Enrollment Status: Recruiting
Publish Date: October 19, 2022
Intervention Type: Other, Diagnostic Test, Drug
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Enrollment Status: Recruiting
Publish Date: October 12, 2022
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
A Phase 1A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
Enrollment Status: Recruiting
Publish Date: September 21, 2022
Intervention Type: Drug
Study Drugs: ETC-1922159Pembrolizumab
Study Phase: Phase 1
An Open-label, Single-Center, Phase 1b/2 Study to Evaluate the Safety of Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Malignancies After Progression on PD-1 or PD-L1 Targeted Antibodies
Enrollment Status: Recruiting
Publish Date: July 01, 2022
Intervention Type: Drug, Biological, Radiation
Study Drugs: AtezolizumabAvelumabDurvalumabNivolumabPembrolizumabPlinabulin
Study Phase: Phase 1/Phase 2
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936 (Anti-ADAM9 Antibody Drug Conjugate) in Patients With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: July 01, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Multicentre, Open-label, Non-randomised First in Human Study of NG-641, an Oncolytic Transgene Expressing Adenoviral Vector, in Patients With Metastatic or Advanced Epithelial Tumours (STAR)
Enrollment Status: Recruiting
Publish Date: March 02, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
Enrollment Status: Recruiting
Publish Date: December 08, 2021
Intervention Type: Biological
Study Drugs: EO2041Nivolumab
Study Phase: Phase 1/Phase 2
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Enrollment Status: Available
Publish Date: December 08, 2022
Intervention Type: Drug
A Phase 1b Study to Evaluate the Safety and Clinical Activity of AB122 in Biomarker-Selected Participants With Advanced Solid Tumors
Enrollment Status: Active, not recruiting
Publish Date: December 08, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies
Enrollment Status: Active, not recruiting
Publish Date: November 30, 2022
Intervention Type: Drug
Study Drug: MAK683
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
Enrollment Status: Active, not recruiting
Publish Date: November 16, 2022
Intervention Type: Drug
Study Drug: TPX-0046
Study Phase: Phase 1/Phase 2
A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second Line Cervical Cancer
Enrollment Status: Completed
Publish Date: November 03, 2022
Intervention Type: Drug
Study Drug: AGEN-2034 PD-1 Antibody
Study Phase: Phase 1/Phase 2
Phase I Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers
Enrollment Status: Active, not recruiting
Publish Date: September 23, 2022
Intervention Type: Other, Drug
Study Phase: Phase 1
A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors
Enrollment Status: Active, not recruiting
Publish Date: September 02, 2022
Intervention Type: Drug, Other
Study Drug: Telaglenastat Hydrochloride
Study Phase: Phase 2
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Enrollment Status: Active, not recruiting
Publish Date: August 15, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Study of TAK-228 (MLN0128) in Combination With Carboplatin Plus Paclitaxel in Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer
Enrollment Status: Completed
Publish Date: April 13, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Enrollment Status: Completed
Publish Date: February 16, 2022
Intervention Type: Drug
Study Drugs: INCAGN01876NivolumabIpilimumab
Study Phase: Phase 1/Phase 2
A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 22, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: November 08, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Trial of Regorafenib and Cetuximab in Patients With Advanced Malignancy
Enrollment Status: Completed
Publish Date: April 01, 2021
Intervention Type: Drug, Behavioral
Study Phase: Phase 1
Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
Enrollment Status: Completed
Publish Date: February 02, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Multi-center, Open-label Dose Escalation and Expansion Study of PCA062 Administered Intravenously in Adult Patients With p-CAD Positive Tumors
Enrollment Status: Completed
Publish Date: December 19, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of HKT288, Administered Intravenously in Adult Patients With Advanced Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma
Enrollment Status: Terminated
Publish Date: December 08, 2020
Intervention Type: Drug
Study Phase: Phase 1
Phase II Trial of Curcumin in Patients With Advanced Pancreatic Cancer
Enrollment Status: Completed
Publish Date: August 28, 2020
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma
Enrollment Status: Terminated
Publish Date: July 16, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf®) in Combination With an mTOR Inhibitor, Everolimus (Afinitor®) or Temsirolimus (Torisel®), in Subjects With Advanced Cancer
Enrollment Status: Completed
Publish Date: June 04, 2020
Intervention Type: Drug
Study Phase: Phase 1
Phase 1/2 Evaluation of Adenoviral p53 (Ad-p53) in Combination With Capecitabine (Xeloda) or Anti-PD-1 in Patients With Unresectable Liver Metastases of Colorectal Carcinoma(CRC) and Other Solid Tumors, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) and Primary Hepatic Cancers With Known Disease Progression on Standard Therapy
Enrollment Status: Terminated
Publish Date: June 02, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
Enrollment Status: Completed
Publish Date: February 11, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: November 08, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Dosimetry, Maximum Tolerated Dose and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by Systemic IV Administration of Escalating Doses of [177Lu]DOTA-biotin in Patients With Solid Tumors or Lymphomas With Injectable Neoplastic Lesions.
Enrollment Status: Terminated
Publish Date: July 05, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 24 Less Clinical Trials -
419 Total Publications
Exportin(g) precision oncology beyond genomics with XPO1 inhibition.
Journal: Med (New York, N.Y.)
Published: November 12, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
KM
Dr. Kenneth L. Mcclain
Pediatric Hematology Oncology | Pediatrics
Highly rated in
8
conditions
Pediatric Hematology Oncology
Pediatrics

Texas Childrens Hospital

Texas Medical Center

6701 Fannin St, 
Houston, TX 
 0.3 mi

Kenneth Mcclain is a Pediatric Hematologist Oncology specialist and a Pediatrics expert in Houston, Texas. Mcclain is highly rated in 8 conditions, according to our data. His top areas of expertise are Langerhans Cell Histiocytosis, Histiocytosis, Reticulohistiocytoma, Non-Langerhans-Cell Histiocytosis, and Bone Marrow Transplant. He is licensed to treat patients in Texas. Mcclain is currently accepting new patients.

RG
Dr. Richard G. Gorlick
Pediatric Hematology Oncology | Hematology | Oncology
Highly rated in
20
conditions
Pediatric Hematology Oncology
Hematology
Oncology

University of Texas System

1515 Holcombe Blvd, 
Houston, TX 

Richard Gorlick is a Pediatric Hematologist Oncology specialist and a Hematologist in Houston, Texas. Gorlick has been practicing medicine for over 33 years and is highly rated in 20 conditions, according to our data. His top areas of expertise are Osteosarcoma, Adult Soft Tissue Sarcoma, Bone Tumor, Ewing Sarcoma, and Bone Marrow Transplant. He is licensed to treat patients in Texas and New York. Gorlick is currently accepting new patients.

HK
Hagop M. Kantarjian
Dr. Hagop M. Kantarjian
Hematology Oncology | Oncology | Hematology
Highly rated in
59
conditions
Hematology Oncology
Oncology
Hematology

University of Texas System

Physicians Referral Service

1515 Holcombe Blvd, 
Houston, TX 

Hagop Kantarjian is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Kantarjian has been practicing medicine for over 44 years and is highly rated in 59 conditions, according to our data. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Texas. Kantarjian is currently accepting new patients.